Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.

Analyst Commentary

Recent research updates on Abbott Laboratories highlight a variety of perspectives regarding the company’s future outlook, valuation, and execution across its key business segments.

• Bullish analysts point to favorable legal outcomes in the ongoing multidistrict litigation over infant formula products. This is suggested to serve as a positive precedent and may reduce future legal uncertainty.
• The company's Medical Devices segment continues to demonstrate strong operating momentum, with underlying performance supporting optimism for continued growth.
• Abbott's diversified business model, spanning multiple therapies, technologies, and geographies, is viewed as providing a resilient foundation for sustainable mid-single digit sales growth and double-digit adjusted EPS increases.
• International expansion and exposure to high-demand healthcare sectors are expected to help offset macroeconomic uncertainty and bolster long-term growth prospects.

• Some bearish analysts have noted a slight reduction in price targets, reflecting headline numbers that fell just short of expectations in recent results.
• Despite overall gains, certain segments within the business are experiencing varied performance and some lumpiness. This has led to a more cautious near-term outlook.
• While core growth rates remain attractive, elevated expectations may place pressure on valuation if the company fails to consistently outperform consensus estimates.

What's in the News

• Abbott repurchased 2,348,997 shares between July 1 and July 31, 2025 for $293.06 million, completing a $5 billion share buyback program that began in December 2021 (Buyback Tranche Update).
• The company reaffirmed its 2025 organic sales growth guidance of 7.5% to 8.0% (excluding COVID-19 testing) and narrowed its expected adjusted diluted EPS range to $5.12 to $5.18, reflecting double-digit growth at the midpoint (Corporate Guidance).
• Health Canada authorized the Esprit BTK System, a first-of-its-kind dissolvable stent for treating chronic limb threatening ischemia below the knee. Clinical trial data showed improved outcomes and fewer repeat procedures compared to balloon angioplasty (Product-Related Announcements).
• Abbott is reported to be in discussions to purchase Synlait Milk Limited's Pokeno plant in New Zealand, a facility for plant-based milk production, as part of Synlait's ongoing asset review (M&A Rumors and Discussions).

Valuation Changes

• Consensus Analyst Price Target has risen slightly from $144.40 to $144.47, reflecting a modest upward adjustment in fair value assessments.
• Discount Rate has increased marginally from 7.50% to 7.58%. This indicates a slightly higher return expectation or perceived risk level among analysts.
• Revenue Growth projection has climbed modestly from 7.43% to 7.49%. This suggests improved optimism for top-line expansion.
• Net Profit Margin is down slightly from 18.01% to 17.99%, representing a very minor decline in expected profitability.
• Future P/E ratio has inched up from 32.85x to 32.93x, which points to a minimal increase in projected market valuation multiples.